Centauri Therapeutics has announced that it has been granted Qualified Infectious Disease Product (QIDP) status by the U.S. Food and Drug Administration (FDA) for its investigational drug CTX-187. This drug is being developed as a treatment for infections caused by Gram-negative bacteria, which are known for their resistance to many existing antibiotics.
The QIDP designation is intended to encourage the development of new antibiotics for serious or life-threatening infections, providing incentives such as fast-track review and extended market exclusivity. Gram-negative bacterial infections are a significant public health concern due to their increasing resistance to treatment options.
Centauri Therapeutics is focused on addressing unmet medical needs in the field of infectious diseases, and the approval of QIDP status for CTX-187 is a significant milestone in their efforts to bring new therapies to market. The company aims to advance CTX-187 through clinical trials to evaluate its safety and efficacy.
Source: news.google.com